Barcelona, Catalonia, Spain
I am a research scientist with more than 11 years of experience in cancer biology, drug discovery, oncology, and translational research, who has been working in Biotech Equity Research for the last 7 years. I earned my Ph.D. uncovering the mechanism of action of the marine-derived drug plocabulin (PharmaMar). As a postdoctoral researcher I performed preclinical studies at Memorial Sloan-Kettering Cancer Center, and investigated new therapeutic strategies to treat cancer at Weill Cornell Medicine. I am currently applying both my science background and my analytical skills in the investment industry, working in Equity Research at Mizuho. I co-authored 23 peer-reviewed journal articles and book chapters, published in the Journal of Humanities of the Weill Cornell Medical College for several years, and served as editor in the MOSF Journal of Science Fiction for over 4 years.
- Covering large- and SMID-cap biotechnology companies. - Preparing and publishing in-depth initiation reports. - Managing model updates and writing notes for companies under coverage.
- Characterizing the mechanism by which epigenetic treatment resensitize refractory and/or resistant B-cell lymphoma patients to subsequent chemotherapy. - Revealing the interconnections between epigenetic treatment and metabolism to improve the efficacy of this class of drugs in B-cell lymphoma patients. - Performing High-Throughput Screening (HTS) to identify selective small-molecule inhibitors for lymphoma cells (cell-based HTS) and inhibitors of transcriptional master regulators (cell free-based HST by employing Alpha Technology, Fluorescence Polarization and Microscale Thermophoresis). - Determining the mechanism of action of selective small-molecule inhibitors of diffuse large B-cell lymphomas. - Trained and supervised medical fellows and lab technicians
- Performed a preclinical evaluation of improved taxol derivatives and novel marine-derived molecules on leukemia and hematopoietic stem cell models. - Determined the preclinical efficacy of a novel DNA cross-linking agent in sarcoma models.
- Identified the mechanism of action of a marine-derived antineoplastic drug currently in Phase II trial development in Europe and US (PM184, PharmaMar). - Optimized several anti-tubulin compounds by performing structure-activity relationship studies. - Trained and supervised graduate students.
- Purified known and unknown compounds from crude marine extracts employing reversed-phase high performance liquid chromatography and nuclear magnetic resonance. - Identified novel bioactive molecules from marine-origin using cell culture.